951 related articles for article (PubMed ID: 17004293)
21. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.
Durbin AP; Karron RA
Clin Infect Dis; 2003 Dec; 37(12):1668-77. PubMed ID: 14689350
[TBL] [Abstract][Full Text] [Related]
22. Induction of balanced immunity in BALB/c mice by vaccination with a recombinant fusion protein containing a respiratory syncytial virus G protein fragment and a CTL epitope.
Zeng RH; Gong W; Fan CF; Wang YF; Mei XG
Vaccine; 2006 Feb; 24(7):941-7. PubMed ID: 16159685
[TBL] [Abstract][Full Text] [Related]
23. The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach.
Bos JM; Rietveld E; Moll HA; Steyerberg EW; Luytjes W; Wilschut JC; de Groot R; Postma MJ
Vaccine; 2007 Sep; 25(39-40):6922-9. PubMed ID: 17707959
[TBL] [Abstract][Full Text] [Related]
24. Recombinant baculovirus-based vaccine expressing M2 protein induces protective CD8
Lee JY; Chang J
J Microbiol; 2017 Nov; 55(11):900-908. PubMed ID: 29076066
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
Belshe RB; Newman FK; Anderson EL; Wright PF; Karron RA; Tollefson S; Henderson FW; Meissner HC; Madhi S; Roberton D; Marshall H; Loh R; Sly P; Murphy B; Tatem JM; Randolph V; Hackell J; Gruber W; Tsai TF
J Infect Dis; 2004 Dec; 190(12):2096-103. PubMed ID: 15551207
[TBL] [Abstract][Full Text] [Related]
26. New strategies for control of respiratory syncytial virus infection.
Nokes JD; Cane PA
Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
[TBL] [Abstract][Full Text] [Related]
27. Response of calves to challenge exposure with virulent bovine respiratory syncytial virus following intranasal administration of vaccines formulated for parenteral administration.
Ellis J; Gow S; West K; Waldner C; Rhodes C; Mutwiri G; Rosenberg H
J Am Vet Med Assoc; 2007 Jan; 230(2):233-43. PubMed ID: 17223757
[TBL] [Abstract][Full Text] [Related]
28. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.
Tang RS; Spaete RR; Thompson MW; MacPhail M; Guzzetta JM; Ryan PC; Reisinger K; Chandler P; Hilty M; Walker RE; Gomez MM; Losonsky GA
Vaccine; 2008 Nov; 26(50):6373-82. PubMed ID: 18822334
[TBL] [Abstract][Full Text] [Related]
29. Respiratory syncytial virus infections: characteristics and treatment.
Chidgey SM; Broadley KJ
J Pharm Pharmacol; 2005 Nov; 57(11):1371-81. PubMed ID: 16259768
[TBL] [Abstract][Full Text] [Related]
30. DNA vaccination against pseudorabies virus and bovine respiratory syncytial virus infections of young animals in the face of maternally derived immunity.
Hamers C; Juillard V; Fischer L
J Comp Pathol; 2007 Jul; 137 Suppl 1():S35-41. PubMed ID: 17553517
[TBL] [Abstract][Full Text] [Related]
31. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases.
Welliver TP; Reed JL; Welliver RC
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S92-6. PubMed ID: 18820587
[TBL] [Abstract][Full Text] [Related]
32. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
[TBL] [Abstract][Full Text] [Related]
33. In vitro model for the assessment of human immune responses to subunit RSV vaccines.
Chirkova T; Ha B; Rimawi BH; Oomens AGP; Hartert TV; Anderson LJ
PLoS One; 2020; 15(3):e0229660. PubMed ID: 32191728
[TBL] [Abstract][Full Text] [Related]
34. The immunomodulating properties of human respiratory syncytial virus and immunostimulating complexes containing Quillaja saponin components QH-A, QH-C and ISCOPREP703.
Hu KF; Regner M; Siegrist CA; Lambert P; Chen M; Bengtsson KL; Morein B
FEMS Immunol Med Microbiol; 2005 Feb; 43(2):269-76. PubMed ID: 15681158
[TBL] [Abstract][Full Text] [Related]
35. Influence of maternal antibodies on neonatal immunization against respiratory viruses.
Crowe JE
Clin Infect Dis; 2001 Nov; 33(10):1720-7. PubMed ID: 11595986
[TBL] [Abstract][Full Text] [Related]
36. Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection.
van Diepen A; Brand HK; de Waal L; Bijl M; Jong VL; Kuiken T; van Amerongen G; van den Ham HJ; Eijkemans MJ; Osterhaus AD; Hermans PW; Andeweg AC
J Virol; 2015 May; 89(9):5022-31. PubMed ID: 25694607
[TBL] [Abstract][Full Text] [Related]
37. Maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from RSV in newborn lambs.
Garg R; Latimer L; Wang Y; Simko E; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Vaccine; 2016 Jan; 34(2):261-269. PubMed ID: 26616551
[TBL] [Abstract][Full Text] [Related]
38. Role of complement in neutralization of respiratory syncytial virus.
Yoder SM; Zhu Y; Ikizler MR; Wright PF
J Med Virol; 2004 Apr; 72(4):688-94. PubMed ID: 14981775
[TBL] [Abstract][Full Text] [Related]
39. Prevention and treatment of respiratory syncytial virus infection in infants: an update.
Venkatesh MP; Weisman LE
Expert Rev Vaccines; 2006 Apr; 5(2):261-8. PubMed ID: 16608425
[TBL] [Abstract][Full Text] [Related]
40. Advances in respiratory syncytial virus vaccine development.
Kneyber MC; Kimpen JL
Curr Opin Investig Drugs; 2004 Feb; 5(2):163-70. PubMed ID: 15043390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
